<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198367</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0101</org_study_id>
    <nct_id>NCT00198367</nct_id>
  </id_info>
  <brief_title>Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2
      account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the
      results obtained by surgery alone or surgery followed by chemotherapy (CT) and/or
      radiotherapy (RT) are insufficient. The neoadjuvant approach was tested, in randomized tests
      of exclusive CT, or in noncomparative tests of RT-CT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      These results justify the choice of the study design currently suggested, testing the
      preoperative feasibility

        1. chemotherapy: cisplatin-Gemzar (arm A) or

        2. chemoradiotherapy: cisplatin-navelbine-radiotherapy (arm B) or
           Carboplatin-Taxol-radiotherapy (arm C).

      The results obtained, in terms of feasibility and toxicity, will make it possible to select
      the optimal diagrams for a phase III study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients alive and operated on without grade 4 toxicity (except for hematological and N/V toxicities)</measure>
    <time_frame>at week 22</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin-Gemzar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin-Gemzar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin-Navelbine-Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin-Navelbine-Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin-Taxol-Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin-Taxol-Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin-Gemzar</intervention_name>
    <arm_group_label>Cisplatin-Gemzar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin-Navelbine-Radiotherapy</intervention_name>
    <arm_group_label>Cisplatin-Navelbine-Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin-Taxol-Radiotherapy</intervention_name>
    <arm_group_label>Carboplatin-Taxol-Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operable and resectable stage IIIA (T1-3, N2) NSCLC

          -  World Health Organization (WHO) performance status of 1 or less

        Exclusion Criteria:

          -  Severe cardiac, respiratory, renal or hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francoise Mornex, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Milleron, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud - Radiotherapie/Oncologie</name>
      <address>
        <city>Pierre-Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>operable and resectable stage IIIA (T1-3, N2) NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

